Medical network on February 14 - February 9, general office of the state council issued "on further reform and improve the use policy for producing and distributing medicines of several opinions" (hereinafter referred to as "opinions"), involved in the production of pharmaceuticals, circulation, use the entire distribution chain, a total of 17, is referred to as the pharmaceutical industry "the 17 countries".
Health under the state council office director, deputy director of the national health and family planning commission Wang Hesheng pointed out that due to historical reasons, the drugs industry "more small scattered difference" of the situation there is no fundamental change, drug quality is uneven, circulation order, prices artificially high, such as drug abuse problem is prominent.
Therefore, the "opinions" resolving the outstanding problems in medical industry, from the pharmaceutical production, circulation, use full chain system reform measures are put forward, improve the quality of medical supplies curative effect, to ensure timely supply, promote the drug price is reasonable, make the drug return to cure source, construction standard and orderly drug supply security system.
Article 9 of the "opinion" is a major breakthrough, "allowing public hospital in the provincial drug centralized purchasing platform (provincial public resources trading platform) combined with quantity, purchasing budget." The personage inside course of study thinks, this means that the national policy file level "no hospitals purchasing drugs secondary bargaining" open "ban", drug prices is inevitable trend.
"How small scattered bad situation could change
Medicine as a special commodity, directly related to people's health and life safety, research used for producing and distributing medicines policy in 2016, has become the national annual key reform tasks.
According to introducing, reform office of the state council, the state food and drug supervision administration departments in many other aspects of extensive research, fully listen to opinions, on the basis of the formation of the "on further reform and improve the use policy for producing and distributing medicines of several opinions (SongShenGao), health reform leading group of the state council examined and approved the central comprehensively deepen reform leading group after the review, and on December 30, 2016, the central comprehensively deepen reform leading group 31 meeting examined and approved, by the state council general office recently issued by the implementation.
On January 25, 2017, the state council reform office director, deputy director of the national health and family planning commission Wang Hesheng briefing held in the state council information office press conference room, points out that medicine is an important content of deepening the reform of medical health system, is the medical treatment, health care, medical reform, scientific and technologic an important link, is to speed up the construction the central task of drug supply security system. But due to historical reasons, the pharmaceutical industry "more small scattered difference" of the situation there is no fundamental change, drug quality is uneven, circulation order, prices artificially high, such as drug abuse problem is prominent.
National food administration of drug safety, according to data from the end of 2015, our country has 5065 pharmaceutical producing enterprises, is the world's largest active pharmaceutical ingredients producer and exporter, is also the world's largest producer, 97% of products for generic drugs, drug homogeneity, low level repeated problems.
Regarding this, wu zhen, deputy chief of the state food administration of drug safety in the briefing, points out that the reform involves the production, circulation, use the link, is the whole process reform, some involve production listed products in the field of the review and approval, and product specifications listed after the regulation and distribution order, this file after printing, to further promote the reform in the field of pharmaceutical production circulation, improve the quality of the pharmaceutical production circulation, and ensure the public will surely play a very active role.
This "opinion" and "2015 44 files are identical. In this file involves the drug approval for examination and approval, the key is to improve the listed drug quality, for example, to classify the listed drugs, new drug is required for a new global generics to the original agreement, can realize mutual substitution; already listed in the drug to do consistency evaluation, prove that the product and the original product. In terms of quality, efficacy listed drug quality promotion, to promote reform of pharmaceutical production enterprise plays a positive role, structural adjustment, to protect the public administration is safe and effective, establish public confidence in the domestic drug also has a positive role." Wu said.
At the same time, "opinion" is put forward to improve medicine circulation order, promote the medicine circulation system reform, to break the pharmaceutical products market segmentation, local protection, medicine circulation promote cross-regional, cross ownership enterprises, mergers and reorganization, nurturing large-scale modern medicine circulation backbone enterprises.
Recent excessive repeated drug announcement shows that there are 129 kinds of pharmaceutical production of more than 100 enterprises at the same time. Pharmaceutical wholesale enterprises across the country have 13508, more than 453000 retail enterprises, the top three pharmaceutical wholesale enterprises market share is only 33%, compared with the developed countries generally in more than 80% of the share is far, industry concentration degree is low, for modern medicine circulation enterprises accounted for only 1.75%.
Drug companies face pressure to cut prices
Look from the "opinions", many reforms directly pointing to "price".
"Opinions" pointed out that Chinese pharmaceutical circulation, circulation disorder, the affiliated business, ticket money laundering, the prohibition of commercial bribery, pushing up prices for drugs, corrosion of doctors, induced the emergence of excessive, expensive medicine.
"Opinion" also mentioned that to carry out drug procurement "two votes", comprehensive reform pilot provinces (autonomous regions and municipalities) and the reform of public hospitals pilot cities to take the lead to implement the "two votes", encouraging other areas implement the "two votes", to win in 2018 opened throughout the country.
Health under the state council office, national health development planning commission deputy director of the full-time TiGaiSi chief priests Liang Wannian has said that the drug from the manufacturer to more ticket link in medical institution, some four votes, five, or even more, layers of overweight, pushing up the price of drugs. Drug price, sales to the medical institutions, on the one hand, people want to pay more, on the other hand, medical insurance fund to pay more.
And there is also a major breakthrough in the "opinions", which clearly put forward: "we will improve the mechanism of drug purchase. Payment in comprehensive health-care reform or make medicare drug payment standard, allowing public hospital in the provincial drug centralized purchasing platform (provincial public resources trading platform) combined with quantity, purchasing budget."
In the past years, in the aspect of national policy documents "prohibit hospitals purchasing drugs secondary bargaining", such as "WeiGui wealth hair [2010] no. 2010" file "about specifications issued by the medical institutions and drug centralized purchasing work notice mentioned that medical institutions in accordance with the contract selling drugs," secondary bargaining "should not be conducted. Strict review for drug purchase invoice, to prevent the procurement, WeiJia purchasing or channels for purchasing drugs from the rules.
While the "opinions" means "ban" big opening, allowing the hospital combined with quantity, procurement budget, equivalent to a given around the hospital drug procurement negotiation can justly, bargain "secondary" has a legal right.
In fact, for "secondary bargaining" has been controversial for years. A number of pharmaceutical companies to the 21st century economy, head of the reporter said, "the second negotiation" has caused many large dosage, efficacy, good quality of drugs was forced to withdraw from the market, seriously affect the safety of the people.
Chinese medicines, such as in March 2016, ningbo bargain "secondary", because in zhejiang province to drug price to drop 15%, on the basis of bidding directory involving 1263 varieties, in the end only 244 varieties gauge (337) won the bid, success rate of less than 20%. Most bid drugs because is close to the cost price to drop, was forced out.
However, China's pharmaceutical enterprise management association, vice President of cows are dry, points out that in the health care reform after landing, is able to resist the "secondary bargaining", will be let go.
People club department has finished joint health development planning commission jointly revised on the pay of insurance of primary medical treatment to drug standard rules of guidance (draft) "(hereinafter referred to as" draft "), again to solicit comments from various ministries and agencies, health care payment standard is expected to formally draft fastest in February, the most late march with the new medicare drug directory. Health insurance payment standard is different from the past in proportion of reimbursement way, its biggest luminescent spot lies in a hospital and health care payment standard sale price gap between, allowing the hospital.
"For businesses, drug prices open low-priced tickets directly, may be relatively easy for companies, financial processing is simple." Cattle are pointed out.
Moreover, the "opinions" also stressed the drugs on the receivable situation as a public hospital dean annual appraisal and an important part of the annual appraisal. "If the hospital can timely collection and is a great good for drug firms, part can hedge price pressure. Hospital for drug firms payback period is 3 months, some even up to half a year or even one year. The longer the payback periods, drug firms to assume the greater the risk." A head listed drug firms to 21st century business herald reporters. |
